ulcerative colitis
Conditions
Interventions
Treatment group:sufficient mesalazine (= 3 grams per day) plus upadacitinib 15mg qd
Control group:sufficient mesalazine (= 3 grams per day) / sufficient mesalazine (= 3 grams per day) plus local suppositories or enemas
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1)Age from 18 to 75; 2)Diagnosed for UC at least 6 months with sufficient mesalazine (= 3 grams per day) for at least 8 weeks, still experiencing diarrhea or bloody stools; 3)Mild active UC patients who meet SFS = 2 points and RBS = 1 point; 4)Tolerate to colonoscopy, participate the study voluntarily and sign the informed consent form
Exclusion criteria
Exclusion criteria: 1)Chronic infectious diseases, including active tuberculosis, herpes zoster, clostridium difficile, hepatitis B virus, hepatitis C virus or other pathogenic microorganisms; 2)Those who are using glucocorticoids, biological agents, immunosuppressants or Chinese herbal medicine/traditional Chinese medicines which preparations with immune regulation in combination; 3)Patients with systemic symptoms such as fever, obvious fatigue, and loss of appetite; 4)Patients with colonic tumors or moderate to severe dysplasia discovered by colonoscopy and confirmed by pathology; 5)Individuals with tumors (not including those who have previously been cured of tumors) 6)Individuals with coagulation dysfunction or thromboembolic diseases (acute myocardial infarction, cerebral infarction/embolism, pulmonary embolism, or other thromboembolic conditions that occur within 6 months), liver and kidney dysfunction, and severe cardiovascular and pulmonary diseases; 7)Individuals with immunodeficiency or human immunodeficiency virus infection; 8)Pregnant and breast-feeding women; 9)Individuals without legal capacity or those with medical or ethical reasons affect the continuation of research; 10)Individuals who are not suitable for participation in this study by researcher's judgement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| mucosal healing rate;histological healing rate;fecal calprotectin;fecal occult blood; | — |
Countries
China
Contacts
Public ContactTian yu
Peking University First Hospital
Outcome results
None listed